×
Scilex Holding Operating Expenses 2021-2024 | SCLX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Scilex Holding operating expenses from 2021 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.
View More
Scilex Holding Operating Expenses 2021-2024 | SCLX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Scilex Holding operating expenses from 2021 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$173B
Vertex Pharmaceuticals (VRTX)
$129.2B
Bristol Myers Squibb (BMY)
$121.3B
Gilead Sciences (GILD)
$120.8B
CSL (CSLLY)
$91.5B
Regeneron Pharmaceuticals (REGN)
$90.7B
GSK (GSK)
$75.3B
Alnylam Pharmaceuticals (ALNY)
$36.1B
Argenex SE (ARGX)
$35.2B
BioNTech SE (BNTX)
$26.1B
Biogen (BIIB)
$25.1B
Illumina (ILMN)
$24B
BeiGene (BGNE)
$20B
Moderna (MRNA)
$16.5B
Incyte (INCY)
$15.7B
Genmab (GMAB)
$15.4B
Vaxcyte (PCVX)
$12.9B
Insmed (INSM)
$12.8B
BioMarin Pharmaceutical (BMRN)
$12.6B
Bio-Techne Corp (TECH)
$11.9B
Sarepta Therapeutics (SRPT)
$11.3B
Exelixis (EXEL)
$10.3B
Revolution Medicines (RVMD)
$10.2B
QIAGEN (QGEN)
$10.1B
Intra-Cellular Therapies (ITCI)
$9.7B
Exact Sciences (EXAS)
$9.5B
Bio-Rad Laboratories (BIO.B)
$9.4B
Roivant Sciences (ROIV)
$8.7B
Repligen (RGEN)
$7.8B
Ascendis Pharma (ASND)
$7.8B